Document Detail

Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
MedLine Citation:
PMID:  16673799     Owner:  NLM     Status:  MEDLINE    
Clobetasol propionate is known to be a very effective treatment for psoriasis; however, its use is limited by potent corticosteroid class related side effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression and atrophogenicity. The aim of this single-center, parallel group, randomized study was to assess the HPA axis suppression potential, atrophogenicity, and ocular tolerability of clobetasol propionate shampoo in 26 patients with scalp psoriasis. Suitable subjects were treated once daily for 4 weeks with clobetasol propionate shampoo, to be rinsed off after 15 minutes or with a leave-on clobetasol propionate gel. The study demonstrated that clobetasol propionate shampoo did not lead to HPA axis suppression or to skin atrophy. Conversely, the gel led to HPA axis suppression and a decrease in skin thickness. Neither formulation had an impact on ocular safety. Despite the short contact application time, the clobetasol propionate shampoo provides similar efficacy results to the gel.
Philippe Andres; Michel Poncet; Sidou Farzaneh; Pascale Soto
Related Documents :
17008459 - Temperature acclimation modifies sinoatrial pacemaker mechanism of the rainbow trout he...
19861939 - Exercise in, and adaptations to a cold environment have no effect on siga.
8335289 - Quaternary environments and the evolution of primates in east asia, with notes on two n...
8148279 - Photoprotective action of emollients in ultraviolet therapy of psoriasis.
1451459 - Monitoring of skin response to sodium lauryl sulphate: clinical scores versus bioengine...
2847369 - Skin irritancy of commercially available alkyl ether sulphate surfactants: is there a d...
7962669 - Pharmacodynamics of racemic and s(-)-atenolol in humans.
8901029 - Electrofusion of zona-free mouse embryonic cells in electrolytes and their development ...
2287049 - Cardiac sports rehabilitation for patients with ischemic heart disease.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  5     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-05-05     Completed Date:  2006-09-25     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  328-32     Citation Subset:  IM    
Galderma R&D, Sophia Antipolis, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Atrophy / chemically induced
Clobetasol / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Drug Administration Schedule
Hair Preparations / chemistry*
Hypothalamo-Hypophyseal System / drug effects,  physiology
Middle Aged
Ocular Physiological Phenomena / drug effects
Pituitary-Adrenal System / drug effects,  physiology
Psoriasis / drug therapy*
Scalp Dermatoses / drug therapy*
Skin / drug effects,  pathology
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Hair Preparations; 25122-41-2/Clobetasol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens.
Next Document:  Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and c...